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capillary injury. This process is biological,
with reversible and irreversible path-
ways4,5 and along a spectrum that cannot
be dichotomous, hence the association of
time, arterial oxygen tension/inspired oxy-
gen fraction (PaO2/FIO2) ratios and radio-
graphic findings that are in the context of
the International Society of Heart and Lung
Transplantation definition. The authors do
not reveal their perioperative bronchoscopy
protocol, which itself can influence radio-
graphic findings with respect to presence or
absence of infiltrates. It is not uncommon
that infiltrates could be due to segmental
and/or subsegmental mucus plugging,
which when it extends to main bronchi can
cause significant ventilation–perfusion
mismatch and reduction of PaO2/FIO2 ra-
tios. The population sample, as quite cor-
rectly stated by the authors, remains small
and heterogeneous; primary pulmonary hy-
pertension is a bilateral problem and re-
quires bilateral lung transplantation. The
authors should analyze their findings with
respect to a clean cohort of infectious lung
disease, for example, to avoid the con-
founding effect of pulmonary hyperten-
sion. The reader will soon realize that the
majority of patients with pulmonary hyper-
tension were among the cohort with bilat-
eral infiltrates.
Moreover, patients with fixed pulmo-
nary hypertension are more likely to expe-
rience reperfusion–ischemic injury with
higher PGD grades.5 Recently, aprotinin
has been shown to reduce reperfusion in-
jury and allograft dysfunction. It is unclear
from the manuscript which antifibrinolytic
was administered during transplantation—
the type of antifibrinolytic being a potential
confounder. The authors state that unilat-
eral infiltrates were associated with PGD
grade 3, but that diminished at T48 hours.
However, when compared with the absence
of infiltrates at T0, it had decreased. It may
be more appropriate to look at the absolute
difference from T0 to T48 rather than the
relative difference, which in a larger homo-
geneous population sample would mini-
mize confounding. Short of radiographic
findings, a clinician can be at loss if PaO2/
FIO2 ratios are the only information pro-
vided to make a diagnosis of PGD and/or to
intervene with medical therapy or bron-
choscopy. Given the therapeutic and diag-
nostic power of bronchoscopy, any infil-
trate on the chest radiograph is of
paramount importance in decision making
and detection of this biological PGD pro-
cess. Furthermore, despite the inherently
subjective interpretation of a chest radio-
graph, a transplant physician can recognize
patterns of unilateral infiltrates that are typ-
ical of the most severe and rapidly pro-
gressing to grade 3 PGD, which could go
unnoticed if only bilateral infiltrates are
considered.
Jeffrey Shuhaiber, MD
Department of Thoracic
and Cardiovascular Surgery
Loyola University Medical Center
Chicago, Ill
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Reply to the Editor:
The aims of our study were to describe the
difference of unilateral and bilateral radio-
graphic infiltrates on early posttransplant
outcomes, including primary graft dysfunc-
tion (PGD) grade.1,2 As Shuhaiber states, a
perioperative bronchoscopy protocol could
influence radiographic findings. In our pro-
tocol, inspection and toileting bronchos-
copy was routinely performed before donor
lung procurement, immediately after im-
plantation, and within 6 hours after admis-
sion to the intensive care unit. Therefore,
significant airway secretions or mucus
plugging were unlikely to be present in the
early postoperative period. Moreover, for
the purpose of PGD grading, only radio-
graphic infiltrates, consistent with pulmo-
nary edema rather than atelectasis, were
assessed (as per the International Society
for Heart and Lung Transplantation PGD
grading guideline.2).
Notwithstanding, mucus plugging, clot,
or extubation itself3 could cause a tempo-
rary reduction of arterial oxygen tension/
fraction of inspired oxygen (PaO2/FIO2) ra-
tio. Therefore, the worst PaO2/FIO2 ratio
might not represent true graft function4 and
should not be used for PGD grading.
Pulmonary hypertension (PH) is a sig-
nificant risk factor for posttransplant radio-
graphic infiltrates. In our study, the number
of patients with PH was small; thus, the
majority of bilateral infiltrates were seen in
the non-PH patient group. Moreover, the
official PGD grading system applies to
both PH and non-PH recipients.
Antifibrinolytic agents were used for
patients having a higher risk of bleeding
(eg, cardiopulmonary bypass, previous tho-
racic operation), patients already at in-
creased risk of postoperative pulmonary in-
filtrates. Therefore, in this circumstance,
the radiographic infiltrates are potentially
multifactorial.
Although further study including multi-
variate analysis is needed, our study clearly
showed that the early posttransplant out-
come of the unilateral infiltrates was simi-
lar to that in the group having a clear chest
x-ray film and significantly better than that
in those with bilateral infiltrates. Therefore,
we believe that in bilateral lung transplan-
tation, only bilateral infiltrates should be
used as part of the definition of PGD.
Takahiro Oto, MDa
Gregory I. Snell, MDb
Department of Thoracic Surgery
Okayama University Hospitala
Okayama, Japan
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Amiodarone and cardiac surgery
To the Editor:
The recent publication of a large random-
ized trial of amiodarone arrhythmia pro-
phylaxis after cardiac surgery (PAPA-
BEAR) is of great interest.1 It was striking
how similar the results of this trial were to
our previous observational analysis of peri-
operative amiodarone during mitral valve
repair,2 and a detailed comparison raises
several points. First, both studies con-
cluded that amiodarone was effective, re-
ducing postoperative atrial arrhythmias by
half and virtually eliminating mortality
from ventricular arrhythmias. Second, seri-
ous complications of a brief perioperative
administration were rare. In PAPABEAR,
bradycardia requiring dose reduction oc-
curred in 5.7% of cases and was considered
a side effect. In clinical practice, however,
postoperative bradycardia can be managed
easily with transient atrial pacing, and re-
duction to a low discharge dose is routine.
Third, only low-risk patients undergoing
elective procedures were randomly as-
signed in PAPABEAR, which limited
event rates and statistical power to define
other clinical benefits, similar to the AFIST
trial.3 The use of large national databases
for such studies could allow better sample
sizes and would certainly be less costly.
The patients most likely to achieve abso-
lute event reductions are those at the very
highest risk (ie, those most prone to non-
fatal and fatal arrhythmias). Those patients
often undergo operation on an emergency
basis and thus are not candidates for a
prolonged preoperative oral protocol.
In the acute setting, 12 hours of stan-
dard intravenous loading (150-mg intra-
venous bolus followed by 1-mg/min in-
travenous infusion for 6 hours and then
0.5-mg/min intravenous infusion) per-
forms well,2 similar to the “hybrid” pro-
tocol of AFIST II.4 The infusion is con-
tinued postoperatively, and additional
150-mg bolus doses are administered ag-
gressively for persistent sinus tachycar-
dia or the appearance of arrhythmias.
Dose reductions are prompted by (1) ob-
served lengthening of the P-R or Q-T
interval or (2) reduction in the underlying
sinus rate to 70 to 80 beats/min. Oral
amiodarone is begun on the first postop-
erative day at 400 mg orally every 6
hours, and the intravenous agent is over-
lapped for 24 hours. Then, the oral dose
is progressively reduced to 200 mg orally
twice daily at discharge, again guided by
optimizing the sinus rate to 70 to 80
beats/min. If the sinus rate is especially
sensitive to the drug, the discharge dose
can be reduced all the way to 100 mg
orally daily. The discharge dose is con-
tinued orally for 3 to 4 weeks after sur-
gery to prevent the occasional “late
breakthrough” and then stopped abruptly,
because amiodarone has a prolonged ef-
fect after discontinuation. If sinus tachy-
cardia is difficult to control, very low
doses of -blockers can be added with
synergistic effect.
After using this approach for more
than 10 years,2 it is now routine for all
cardiac procedures, with a clinical expe-
rience that parallels PAPABEAR. Abso-
lute benefits, however, are even more im-
pressive in high-risk patients. Aggressive
and routine arrhythmia prophylaxis with
this safer and more effective agent has
been a major advance in the care of car-
diac surgical patients. This approach
could significantly reduce the current rate
of postoperative arrhythmias, which have
occurred in as many as a third of cardiac
patients in recent series.5
J. Scott Rankin, MD
Centennial Medical Center
Vanderbilt University
Nashville, Tenn
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